View Author
cancer patient breast breast cancer treatment study chemotherapy doxorubicin effect metastatic breast cancer therapy growth response chapter breast cancer cells survival group result combination factor metastatic trial catheter tumor cycle disease oncol table trastuzumab month mcf -7 cells hormone cell cycle randomized culture number netherland epirubicin tamoxifen high-dose chemotherapy toxicity phase infection incubation estradiol breast cancer patients figure uptake etoposide oestradiol sample duration receptor high-dose serum cytotoxic protein h ¡d group estrogen difference somatostatin haptoglobin range analysis recruitment agent h ϩd group percentage estrogenic recruitment s-phase catheter-related center medium control analogue docetaxel phase ii study phenotype neutropenia protocol
8 Most Recent Publications
|
Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer
(Article)
Gast, M.C.W. Zapatka, M. Tinteren, H. van Bontenbal, M. Span, P.N. Tjan-Heijnen, V.C.G. Knol, J.C. Jimenez, C.R. Schellens, J.H.M. Beijnen, J.H. |
2011-12-01
|
|
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: Hertax trial
(Article)
Hamberg, P. Bos, M.M.E.M. Pruijt, J.F.M. Loosveld, O.J.L. Smit, W.M. Muller, E.W. Schmitz, P.I.M. Seynaeve, C.M. Klijn, J.G.M. Braun, H.J.J. Stouthard, J.M.L. Deijk, G.A. van Erdkamp, F.L.G. Stelt-Frissen, I.N. van der Bontenbal, M. Creemers, G.J.M. Portielje, J.E.A. |
2011-04-01
|
|
Multimodality treatment for anaplastic thyroid carcinoma - Treatment outcome in 75 patients
(Article)
Swaak-Kragten, A.T. Wilt, J.H.W. de Schmidtz, P.I. Bontenbal, M. Levendag, P.C. |
2009-07-01
|
|
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients
(Article)
Gast, M.C.W. Tinteren, H. van Twisk, J.W. Schellens, J.H. Beijnen, J.H. Bontenbal, M. Hoesel, R.Q.G.C.M. van Nooij, M.A. Rodenhuis, S. Span, P.N. Tjan-Heijnen, V.C.G. Vries, E. de Harris, N. |
2008-12-24
|
|
Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients
(Article)
Nieboer, P. Vries, E.G.E. de Nooij, M.A. Boezen, H.M. Graaf, W.T.A. van der Mulder, N.H. Rodenhuis, S. Bontenbal, M. Wall, E.E. van der Hoesel, Q.G. van Smit, W.M. Hupperets, P. Voest, E.E. |
2008-07-15
|
|
Granulocyte colony-stimulating factor: Key (F)actor or innocent bystander in the development of secondary myeloid malignancy?
(Article)
Touw, I.P. Bontenbal, M. |
2007-02-01
|
|
Clinical experience with venlafaxine in the treatment of hot flushes in women with a history of breast cancer
(Article)
Gool, A.R. van Bannink, M. Bontenbal, M. Seynaeve, C.M. |
2005-01-01
|
|
Systemic Treatment Approaches in Breast Cancer
(Doctoral Thesis)
Bontenbal, M. |
1997-06-04
|
